重组人干扰素α2b凝胶联合阿奇霉素治疗慢性宫颈炎伴HPV感染患者的临床疗效

doi:10.3969/j.issn.1671-7171.2024.04.026

摘要
图/表
参考文献
相关文章 (9)

全文: PDF (1162 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨重组人干扰素α2b凝胶联合阿奇霉素治疗慢性宫颈炎伴人乳头瘤病毒(HPV)感染患者的临床疗效。【方法】选取2021年3月至2023年3月本院收治的110例慢性宫颈炎伴HPV感染患者,按随机数字表法分为对照组和观察组,每组55例。对照组采用重组人干扰素α2b凝胶治疗,观察组采用重组人干扰素α2b凝胶联合阿奇霉素治疗,均治疗14 d。比较两组患者临床疗效、乳酸杆菌减少率、白细胞酯酶(LE)阳性率、凝固酶(GADP)阳性率、阴道pH值>4.5占比、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-8(IL-8)]水平、HPV病毒载量、HPV转阴率及疾病复发率。【结果】观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组乳酸杆菌减少率、LE阳性率、GADP阳性率、阴道pH值>4.5占比均高于对照组,差异有统计学意义(P<0.05)。治疗前,两组炎症因子水平比较,差异无统计学意义(P>0.05);治疗后,观察组TNF-α、IL-1β、IL-8水平均低于对照组,差异有统计学意义(P<0.05)。治疗后,两组病毒载量均下降,且观察组病毒载量低于对照组,差异有统计学意义(P<0.05)。观察组HPV转阴率高于对照组,复阳率、疾病复发率低于对照组,差异有统计学意义(P<0.05)。【结论】重组人干扰素α2b凝胶联合阿奇霉素治疗慢性宫颈炎伴HPV感染患者的效果显著,可降低炎症因子水平,减少HPV病毒载量,促进HPV转阴,值得临床推广。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谢菲
	李双

关键词 ：宫颈炎/药物疗法, 乳头状瘤病毒感染/药物疗法, 干扰素α2, 叠氮红霉素

Abstract：【Objective】To explore the application effect of recombinant human interferon α2b gel combined with azithromycin in patients with chronic cervicitis with HPV infection. 【Methods】A total of 110 patients with chronic cervicitis with HPV infection who were admitted to the XD Group Hospital from March 2021 to March 2023 were selected as the research objects. They were divided into the control group and the observation group by random number table method, with 55 cases in each group. The control group was treated with recombinant human interferon α2b gel, while the observation group was treated with recombinant human interferon α2b gel combined with azithromycin. Both treatments were for a course of 2 weeks. The clinical efficacy, Lactobacillus reduction rate, leukocyte esterase (LE) test and coagulase (GADP), vaginal pH value, inflammation factors [tumor necrosis factor-α (TNF-α), interleukin-1β(IL-1β), interleukin-8(IL-8)]level, HPV virus load, conversion rate, and recurrence rate of the two groups were compared. 【Results】The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). The reduction rate of Lactobacillus, positive rate of LE, positive rate of GADP, and proportion of vaginal pH value >4.5 in the observation group were all higher than those in the control group, and the differences were statistically significant (P<0.05). Before treatment, there was no statistical significance in the comparison of inflammation factors between the two groups (P>0.05). After treatment, the levels of TNF-α, IL-1β, and IL-8 in the observation group were lower than those in the control group, the difference was statistically significant (P<0.05). After treatment, the virus load of both groups decreased, while the virus load of the observation group was lower than that of the control group, and the difference was statistically significant (P<0.05). The HPV negative conversion rate of the observation group was higher than that of the control group, the HPV recurrence rate and the disease recurrence rate in the observation were lower than those in the control group, and the differences were statistically significant (P<0.05). 【Conclusion】Recombinant human interferon α2b gel combined with azithromycin has significant effects in patients with chronic cervicitis with HPV infection. It can reduce inflammation, reduce HPV virus load, promote HPV negative conversion, which is worth promoting.

Key words： Uterine Cervicitis/DT Papillomavirus Infections/DT Interferon alpha-2 Azithromycin

收稿日期: 2023-06-30

中图分类号:

R711.32

通讯作者: ^*E-mail:m15029222138-1@163.com

引用本文:

谢菲, 李双. 重组人干扰素α2b凝胶联合阿奇霉素治疗慢性宫颈炎伴HPV感染患者的临床疗效[J]. 医学临床研究, 2024, 41(4): 572-575.
XIE Fei, LI Shuang. Effects of Using Recombinant Human Interferon α2b Gel in Combination with Azithromycin in Patients with Chronic Cervicitis Accompanied by HPV Infection. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 572-575.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.04.026 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I4/572

[1] 马艳芬,毕颖,陈艳玲. 重组人IFNα2b凝胶联合冷冻治疗老年慢性宫颈炎合并HPV感染的临床疗效及对IL-12、IFN-γ、IL-4、IL-10水平的影响[J].中国老年学杂志,2023,43(8):1872-1875.
[2] 何晶,张烽,朱佳尔. 抗HPV生物蛋白敷料与重组人干扰素α-2b凝胶治疗高危型HPV感染的研究[J].中华医院感染学杂志,2020,30(3):403-408.
[3] 吕小可,陈莉,代雪莹. 阿奇霉素与保妇康栓联用对慢性宫颈炎伴HPV感染的结局影响[J].贵州医药,2021,45(9):1419-1420.
[4] 谢幸,苟文丽.妇产科学[M].8版.北京:人民卫生出版社,2013:255-256.
[5] 孙传兴.临床疾病诊断依据治愈好转标准[M].北京:人民军医出版社,2002: 530-531.
[6] 张海琴,刘娟娟,娄俊丽,等. 慢性宫颈炎患者HPV感染状况、基因型分布及其与阴道微生态指标的相关性研究[J].海南医学,2022,33(4):464-467.
[7] 龚娅,段德令,史秋霞,等. 阴道分泌物功能酶检测联合常规镜检在阴道微生态改变中的应用价值[J].国际检验医学杂志,2019,40(20):2491-2493.
[8] 周茜. COOK双球囊联合缩宫素对妊娠晚期产妇宫颈成熟度、引产效果及血清TNF-α、IL-8和IL-1β水平的影响[J].中国现代医药杂志,2022,24(1):43-47.
[9] 李莉,朱颖军,高静,等. CKC联合重组人干扰素α-2 b凝胶治疗宫颈上皮内瘤变Ⅱ级疗效及预后影响因素分析[J].中国计划生育学杂志,2022,30(10):2213-2217.
[10] 李倩,李瑞平,王琳琳. AV/BV五联检阴道微生态异常与高危型HPV感染的相关性分析[J].中国处方药,2020,18(4):173-174.
[11] 韦彩素,陈慧峰,李建湘,等. 子宫颈病变患者阴道微生态环境与HR-HPV感染的相关性及子宫颈病变的影响因素分析[J].中外医学研究,2021,19(17):4-7.
[12] 王晓东. 阿奇霉素与保妇康栓联用对慢性宫颈炎伴HPV感染LEEP术后预后及复发的影响[J].泰山医学院学报,2020,41(4):269-271.
[13] 常玉梅,张凤喜,王薇,等. 复方沙棘籽油栓联合重组人干扰素α2b凝胶治疗慢性宫颈炎合并高危型人乳头瘤病毒感染疗效观察[J].河北中医,2021,43(6):969-971.
[14] 周蕊,高艳红,田梦蝶. 抗宫炎片联合重组人干扰素α2b凝胶治疗慢性宫颈炎的效果[J].中国医药导报,2020,17(8):97-100.
[15] 董鹂芸,张晴,韩变利. 清热化湿解毒汤联合重组人干扰素α-2b治疗宫颈炎合并HPV感染患者的效果[J].海南医学,2022,33(8):1020-1023.
[16] 李淑华,杨焱,余受益. 妇科排毒汤联合西药治疗慢性宫颈炎合并HPV感染的疗效及对病毒载量的影响[J].世界中西医结合杂志,2021,16(7):1279-1283.